Ionis proposes public offering of common stock; no size or price disclosed

IONIS PHARMACEUTICALS INC

Filed preliminary prospectus supplement on Sep 9, 2024 for a registered underwritten public offering of common stock.
No specific number of shares, price range, or use of proceeds disclosed; offering subject to market conditions.
Business update in supplement notes five marketed drugs, nine Phase 3 programs, and key milestones like olezarsen PDUFA Dec 19, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.